213 related articles for article (PubMed ID: 22558206)
1. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
Sundby RT; Rhodes SD; Komlodi-Pasztor E; Sarnoff H; Grasso V; Upadhyaya M; Kim A; Evans DG; Blakeley JO; Hanemann CO; Bettegowda C
Clin Trials; 2024 Feb; 21(1):40-50. PubMed ID: 37904489
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract][Full Text] [Related]
6. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
[TBL] [Abstract][Full Text] [Related]
7. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
Vasudevan HN; Payne E; Delley CL; John Liu S; Mirchia K; Sale MJ; Lastella S; Nunez MS; Lucas CG; Eaton CD; Casey-Clyde T; Magill ST; Chen WC; Braunstein SE; Perry A; Jacques L; Reddy AT; Pekmezci M; Abate AR; McCormick F; Raleigh DR
Nat Commun; 2024 Jan; 15(1):477. PubMed ID: 38216572
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
[TBL] [Abstract][Full Text] [Related]
10. The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis.
Freier A; Lawson McLean AC; Loeschner D; Rosahl SK; Kruse J
Sci Rep; 2024 Mar; 14(1):6934. PubMed ID: 38521834
[TBL] [Abstract][Full Text] [Related]
11. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Gross AM; Plotkin SR; Watts NB; Fisher MJ; Klesse LJ; Lessing AJ; McManus ML; Larson AN; Oberlander B; Rios JJ; Sarnoff H; Simpson BN; Ullrich NJ; Stevenson DA
Clin Trials; 2024 Feb; 21(1):29-39. PubMed ID: 37772407
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for imaging tumor response in neurofibromatosis clinical trials.
Dombi E; Ardern-Holmes SL; Babovic-Vuksanovic D; Barker FG; Connor S; Evans DG; Fisher MJ; Goutagny S; Harris GJ; Jaramillo D; Karajannis MA; Korf BR; Mautner V; Plotkin SR; Poussaint TY; Robertson K; Shih CS; Widemann BC;
Neurology; 2013 Nov; 81(21 Suppl 1):S33-40. PubMed ID: 24249804
[TBL] [Abstract][Full Text] [Related]
13. Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Widemann BC
Neurology; 2013 Nov; 81(21 Suppl 1):S1-5. PubMed ID: 24249801
[TBL] [Abstract][Full Text] [Related]
14. Whole-body MR imaging for improved detection of neurofibromatosis: an integrated technical note to estimate true extent.
Theodorou DJ; Theodorou SJ; Petsanas AP
Neurosurg Rev; 2023 Sep; 46(1):236. PubMed ID: 37682365
[No Abstract] [Full Text] [Related]
15. Whole-body MRI in children: state of the art.
Gaunt T; Humphries PD
BJR Open; 2022; 4(1):20210087. PubMed ID: 38525168
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of schwannomatosis: a retrospective analysis of 87 patients.
Merker VL; Esparza S; Smith MJ; Stemmer-Rachamimov A; Plotkin SR
Oncologist; 2012; 17(10):1317-22. PubMed ID: 22927469
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Findings in Neurofibromatosis Type 1.
Ozarslan B; Russo T; Argenziano G; Santoro C; Piccolo V
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530415
[TBL] [Abstract][Full Text] [Related]
18. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis type 1: a multidisciplinary approach to care.
Hirbe AC; Gutmann DH
Lancet Neurol; 2014 Aug; 13(8):834-43. PubMed ID: 25030515
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
